Marcin Krawczyk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2448489/publications.pdf Version: 2024-02-01

		117625	155660
148	3,874	34	55
papers	citations	h-index	g-index
151	151	151	5151
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut, 2023, 72, 381-391.	12.1	19
2	Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship. European Journal of Clinical Investigation, 2022, 52, e13622.	3.4	63
3	Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut, 2022, 71, 1141-1151.	12.1	32
4	Key summary of German national treatment guidance for hospitalized COVID-19 patients. Infection, 2022, 50, 93-106.	4.7	30
5	Hypophosphatasia: An Underappreciated Cause of Atraumatic Stress Fractures. American Journal of Medicine, 2022, 135, e18-e19.	1.5	1
6	Acute cholestatic liver injury following carbimazole treatment in a patient with VPS33B haploinsufficiency. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101803.	1.5	1
7	Epigastric Pain After COVID-19 Vaccination. American Journal of Gastroenterology, 2022, 117, 371-371.	0.4	2
8	Machine learning models predicting decompensation in cirrhosis. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0
9	Elevated serum bile acids in NASH patients with fibrosis in the context of their cholestatic genetic predisposition. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0
10	Common variant p. <scp>D</scp> 19 <scp>H</scp> of the hepatobiliary sterol transporter <scp><i>ABCG8</i></scp> increases the risk of gallstones in children. Liver International, 2022, 42, 1585-1592.	3.9	9
11	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 2022, 76, 1109-1121.	3.7	119
12	Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis. International Journal of Molecular Sciences, 2022, 23, 2636.	4.1	11
13	Successful EUS-guided Hepaticogastrostomy in a Patient with Intrahepatic Cholangiocarcinoma after Right Hemihepatectomy and Roux-en-Y Anastomosis. Journal of Gastrointestinal and Liver Diseases, 2022, 31, 10-10.	0.9	0
14	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology, 2022, 76, 1121-1134.	7.3	31
15	Liver stiffness as surrogate parameter in emergency assessment for inpatient health care utilization. PLoS ONE, 2022, 17, e0266069.	2.5	0
16	A Novel Mock Circuit to Test Full-Flow Extracorporeal Membrane Oxygenation. Membranes, 2022, 12, 493.	3.0	4
17	TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study. International Journal of Infectious Diseases, 2022, 122, 178-187.	3.3	15
18	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. Hepatology, 2021, 73, 2311-2325.	7.3	40

#	Article	IF	CITATIONS
19	Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis. Liver International, 2021, 41, 348-356.	3.9	16
20	Genetic insight into COVIDâ€19 related liver injury: A note on <i>MBOAT7</i> . Liver International, 2021, 41, 1157-1159.	3.9	5
21	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal of Hepatology, 2021, 74, 20-30.	3.7	77
22	Amiodarone and hypothyroidism. Lancet, The, 2021, 397, 704.	13.7	3
23	Unresectable malignant obstructive jaundice: a 2-year experience of EUS-guided biliary drainage. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2020-002335.	1.6	1
24	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	2.2	63
25	Increased B ell activity with consumption of activated monocytes in severe COVIDâ€19 patients. European Journal of Immunology, 2021, 51, 1449-1460.	2.9	10
26	Chronic Fatigue Persists in a Significant Proportion of Female Patients After Transplantation for Primary Sclerosing Cholangitis. Liver Transplantation, 2021, 27, 1032-1040.	2.4	5
27	Combined analysis of gut microbiota, diet and <i>PNPLA3</i> polymorphism in biopsyâ€proven nonâ€alcoholic fatty liver disease. Liver International, 2021, 41, 1576-1591.	3.9	11
28	Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. Frontiers in Medicine, 2021, 8, 683250.	2.6	34
29	Epithelia-Sensory Neuron Cross Talk Underlies Cholestatic Itch Induced by Lysophosphatidylcholine. Gastroenterology, 2021, 161, 301-317.e16.	1.3	57
30	REPLY:. Hepatology, 2021, 74, 1129-1131.	7.3	2
31	REPLY:. Hepatology, 2021, 74, 2319-2321.	7.3	1
32	Noncommunicable diseases, climate change and iniquities: What COVIDâ€19 has taught us about syndemic. European Journal of Clinical Investigation, 2021, 51, e13682.	3.4	20
33	Distinct Patterns of Blood Cytokines Beyond a Cytokine Storm Predict Mortality in COVID-19. Journal of Inflammation Research, 2021, Volume 14, 4651-4667.	3.5	24
34	Antiâ€glycoprotein 2 (antiâ€GP2) IgA and antiâ€neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3â€ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 302-313.	3.7	19
35	Impact of Endocrine Disorders on the Liver. Endocrinology, 2021, , 157-177.	0.1	0
36	MARC1 p.A165T variant is associated with decreased markers of liver injury and enhanced antioxidant capacity in autoimmune hepatitis. Scientific Reports, 2021, 11, 24407.	3.3	10

#	Article	IF	CITATIONS
37	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. Hepatology, 2020, 72, 88-102.	7.3	76
38	Risk of chemotherapy-associated liver injury (CALI) in PNPLA3 p.148M allele carriers: Preliminary results of a transient elastography-based study. Digestive and Liver Disease, 2020, 52, 102-106.	0.9	1
39	Acute Pancreatitis in the Setting of Hepatitis E Virus (Genotype 3) Infection and Compound CLDN2-PRSS1 Risk Variants. Pancreas, 2020, 49, e91-e93.	1.1	4
40	COVIDâ€19: Focus on the lungs but do not forget the gastrointestinal tract. European Journal of Clinical Investigation, 2020, 50, e13276.	3.4	45
41	Liver Phenotypes of European Adults Heterozygous or Homozygous for Piâ^—Z Variant of AAT (Piâ^—MZ vs) Tj E	1Qq1310	.784314 rgB⊤
42	Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools. Scientific Reports, 2020, 10, 9385.	3.3	20
43	Hepatic consequences of COVID-19 infection. Lapping or biting?. European Journal of Internal Medicine, 2020, 77, 18-24.	2.2	86
44	The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia. Autoimmunity Highlights, 2020, 11, 6.	3.9	6
45	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells, 2020, 9, 721.	4.1	63
46	COVIDâ€19 and nonâ€alcoholic fatty liver disease: Two intersecting pandemics. European Journal of Clinical Investigation, 2020, 50, e13338.	3.4	104
47	Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation. Liver International, 2020, 40, 3103-3116.	3.9	20
48	Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in Management. Hepatology Communications, 2020, 4, 399-408.	4.3	6
49	Common variation in FAM155A is associated with diverticulitis but not diverticulosis. Scientific Reports, 2020, 10, 1658.	3.3	9
50	Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond. Gastroenterology, 2020, 158, 1865-1880.e1.	1.3	76
51	Childhood obesity, cardiovascular and liver health: a growing epidemic with age. World Journal of Pediatrics, 2020, 16, 438-445.	1.8	48
52	Phenotyping nonâ€alcoholic fatty liver disease by the gut microbiota: Ready for prime time?. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1969-1977.	2.8	27
53	High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. Hepatology Communications, 2020, 4, 681-695.	4.3	28
54	Gastrointestinal endoscopy during extracorporeal membrane oxygenation (ECMO) for COVID-19. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 471-473.	0.9	3

#	Article	IF	CITATIONS
55	Modifiable Factors and Genetic Predisposition Associated with Gallbladder Cancer. A Concise Review. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 339-348.	0.9	8
56	Genetic Risk Factors for Autoimmune Thyroid Disease might Affect the Susceptibility to and Modulate the Progression of Primary Biliary Cholangitis. Journal of Gastrointestinal and Liver Diseases, 2020, 26, 245-252.	0.9	11
57	Impact of Endocrine Disorders on the Liver. Endocrinology, 2020, , 1-21.	0.1	Ο
58	Plasmapheresis improves chronic fatigue in patients with primary biliary cholangitis. Polish Archives of Internal Medicine, 2020, 131, 205-207.	0.4	4
59	Genetic variant c.711A>T in the hepatobiliary phospholipid transporter ABCB4 is associated with significant liver fibrosis. Journal of Physiology and Pharmacology, 2020, 71, .	1.1	Ο
60	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 2019, 68, 1099-1107.	12.1	100
61	FRI-032-Liver transplantation ameliorates chronic fatigue and improves quality of life in patients with primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, e398.	3.7	0
62	miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease. Molecular Metabolism, 2019, 29, 40-54.	6.5	35
63	Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Alimentary Pharmacology and Therapeutics, 2019, 50, 580-589.	3.7	67
64	FRI-028-Spleen stiffness and liver stiffness measurements as surrogate markers of liver fibrosis in patients with autoimmune hepatitis: prospective, single-center study. Journal of Hepatology, 2019, 70, e396.	3.7	0
65	FRI-268-Microbiota signature differs significantly between NAFLD and healthy controls but not between NAFL and NASH. Journal of Hepatology, 2019, 70, e512.	3.7	Ο
66	Hepatic steatosis in patients with acromegaly. Endocrinology, Diabetes and Metabolism, 2019, 2, e00090.	2.4	10
67	FRI-294-Mitochondrial GNMT-complex II is recovered by miR-873-5p targeting in NAFLD. Journal of Hepatology, 2019, 70, e524-e525.	3.7	0
68	Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection. Journal of Clinical Medicine, 2019, 8, 103.	2.4	7
69	Non-Alcoholic Fatty Liver Disease in Non-Obese Individuals: Prevalence, Pathogenesis and Treatment. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 638-645.	1.5	33
70	PS-177-HSD17B13 rs72613567 TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis. Journal of Hepatology, 2019, 70, e109-e110.	3.7	5
71	Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?. Liver International, 2019, 39, 32-42.	3.9	21
72	Genetics of gallstone disease revisited. Current Opinion in Gastroenterology, 2019, 35, 82-87.	2.3	11

#	Article	IF	CITATIONS
73	Depression: An Overlooked Villain in Autoimmune Hepatitis?. Hepatology, 2019, 70, 2232-2233.	7.3	9
74	Fat and Sugar—A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease. Nutrients, 2019, 11, 2871.	4.1	14
75	Autoimmune hepatitis exerts a profound, negative effect on healthâ€related quality of life: A prospective, singleâ€centre study. Liver International, 2019, 39, 215-221.	3.9	34
76	Effect of S-Adenosyl-L-Methionine on Liver Biochemistry and Quality of Life in Patients with Primary Biliary Cholangitis Treated with Ursodeoxycholic Acid. A Prospective, Open Label Pilot Study. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 273-279.	0.9	26
77	Short-term Dietary Interventions for the Management of Nonalcoholic Fatty Liver. Current Medicinal Chemistry, 2019, 26, 3483-3496.	2.4	3
78	Secondary systemic amyloidosis diagnosed by endoscopic ultrasound-guided liver biopsy. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 101-105.	0.9	2
79	Depression in autoimmune hepatitis: a need for detailed psychiatric assessment. Polish Archives of Internal Medicine, 2019, 129, 645-647.	0.4	4
80	Effects of Gene Variants Controlling Vitamin D Metabolism and Serum Levels on Hepatic Steatosis. Digestion, 2018, 97, 298-308.	2.3	6
81	Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers. Journal of Human Genetics, 2018, 63, 621-626.	2.3	29
82	Genetics of gallstone disease. European Journal of Clinical Investigation, 2018, 48, e12935.	3.4	38
83	Can genetic testing guide the therapy of cholestatic pruritus? A case of benign recurrent intrahepatic cholestasis type 2 with severe nasobiliary drainageâ€refractory itch. Hepatology Communications, 2018, 2, 152-154.	4.3	Ο
84	Selective association of nonaspirin NSAIDs with risk of diverticulitis. International Journal of Colorectal Disease, 2018, 33, 423-430.	2.2	13
85	A Variant of COL3A1 (rs3134646) Is Associated With Risk of Developing Diverticulosis in White Men. Diseases of the Colon and Rectum, 2018, 61, 604-611.	1.3	25
86	Genetic determinants of cholangiopathies: Molecular and systems genetics. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1484-1490.	3.8	27
87	Reply to: "Diagnostic and prognostic role of circulating microparticles in hepatocellular carcinoma― Journal of Hepatology, 2018, 68, 203-204.	3.7	Ο
88	Gut Permeability Might be Improved by Dietary Fiber in Individuals with Nonalcoholic Fatty Liver Disease (NAFLD) Undergoing Weight Reduction. Nutrients, 2018, 10, 1793.	4.1	56
89	Effects of liver transplantation on healthâ€related quality of life in patients with primary biliary cholangitis. Clinical Transplantation, 2018, 32, e13434.	1.6	9
90	PNPLA3 p.1148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC. PLoS ONE, 2018, 13, e0202942.	2.5	7

#	Article	IF	CITATIONS
91	Successful DAA-Based Treatment of HCV-Related Fibrosing Cholestatic Hepatitis After Liver Transplantation Due to a Fulminant Liver Failure. American Journal of Gastroenterology, 2018, 113, 1062-1063.	0.4	2
92	EUS-guided reconstruction of the biliary system in a patient post right hemihepatectomy. Digestive and Liver Disease, 2018, 50, 863-864.	0.9	0
93	Exercising the hepatobiliaryâ€gut axis. The impact of physical activity performance. European Journal of Clinical Investigation, 2018, 48, e12958.	3.4	48
94	Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 282-292.	3.7	123
95	The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm. Hepatology, 2017, 66, 666-667.	7.3	7
96	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2017, 66, 1125-1143.	7.3	218
97	Does transient elastography correlate with liver fibrosis in patients with PSC? Laennec score-based analysis of explanted livers. Scandinavian Journal of Gastroenterology, 2017, 52, 1407-1412.	1.5	14
98	NOD2 gene variants confer risk for secondary sclerosing cholangitis in critically ill patients. Scientific Reports, 2017, 7, 7026.	3.3	9
99	Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. Journal of Lipid Research, 2017, 58, 247-255.	4.2	159
100	Plasmapheresis exerts a longâ€lasting antipruritic effect in severe cholestatic itch. Liver International, 2017, 37, 743-747.	3.9	20
101	Search for Genetic Modifiers of PSC: Time to Increase the Number of Needles in the Haystack. Annals of Hepatology, 2017, 16, 830-831.	1.5	3
102	Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease. PLoS ONE, 2017, 12, e0173506.	2.5	20
103	Predictive Serum Markers of Gallstone Disease. Journal of Pediatric Gastroenterology and Nutrition, 2017, 64, 337-338.	1.8	2
104	Mice studies disentangle the role of estrogen in gallstone formation. Annals of Hepatology, 2016, 15, 141-142.	1.5	0
105	PNPLA3 p.1148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surgery for Obesity and Related Diseases, 2016, 12, 1838-1846.	1.2	60
106	Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases. Scientific Reports, 2016, 6, 30847.	3.3	48
107	Secondary sclerosing cholangitis rapidly leading to liver cirrhosis: a possible post-ICU treatment sequel. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 119-120.	0.5	3
108	Reduction of Caloric Intake Might Override the Prosteatotic Effects of the <i>PNPLA3</i> p.1148M and <i>TM6SF2</i> p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study. Digestion, 2016, 93, 139-148.	2.3	27

#	Article	IF	CITATIONS
109	The common <i><scp>PNPLA</scp>3</i> variant p.1148M is associated with liver fat contents as quantified by controlled attenuation parameter (<scp>CAP</scp>). Liver International, 2016, 36, 418-426.	3.9	24
110	Tumour-associated circulating microparticles: A novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia. Oncotarget, 2016, 7, 30867-30875.	1.8	33
111	Heterozygous Inactivation of the Nuclear Receptor PXR/NR1I2 in a Patient With Anabolic Steroid-Induced Intrahepatic Cholestasis. Hepatitis Monthly, 2016, 16, e35953.	0.2	5
112	Variant adiponutrin confers genetic protection against cholestatic itch. Scientific Reports, 2015, 4, 6374.	3.3	6
113	Effects of dietary education, followed by a tailored fructose-restricted diet in adults with fructose malabsorption. European Journal of Gastroenterology and Hepatology, 2015, 27, 785-796.	1.6	20
114	The Frequent Adiponutrin (PNPLA3) Variant p.lle148Met Is Associated with Early Liver Injury: Analysis of a German Pediatric Cohort. Gastroenterology Research and Practice, 2015, 2015, 1-6.	1.5	8
115	HCC and liver disease risks in homozygous PNPLA3 p.1148M carriers approach monogenic inheritance. Journal of Hepatology, 2015, 62, 980-981.	3.7	42
116	The PNPLA3 p.lle148Met Variant and Obesity: brothers-in-arms. Surgery for Obesity and Related Diseases, 2015, 11, 894-896.	1.2	0
117	Incarcerated Umbilical Hernia After Colonoscopy in a Cirrhotic Patient. American Journal of Medicine, 2015, 128, e13-e14.	1.5	1
118	Vitamin D deficiency is associated with mortality in patients with advanced liver cirrhosis. European Journal of Clinical Investigation, 2014, 44, 176-183.	3.4	58
119	The inulin hydrogen breath test predicts the quality of colonic preparation. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 1579-1587.	2.4	7
120	Healthy PNPLA3 risk allele carriers present with unexpected body fat composition. A study of one thousand subjects. Journal of Gastrointestinal and Liver Diseases, 2014, 23, 33-7.	0.9	2
121	Liver fibrosis: How many samples in transjugular liver biopsy are sufficient? Histological vs. clinical value. Abdominal Imaging, 2013, 38, 461-464.	2.0	9
122	Splenosis Mimicking Hepatic Adenoma. Journal of Clinical and Experimental Hepatology, 2013, 3, 351-352.	0.9	6
123	Genetics of biliary lithiasis from an ethnic perspective. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 119-125.	1.5	21
124	Modeling hepatic osteodystrophy in Abcb4 deficient mice. Bone, 2013, 55, 501-511.	2.9	20
125	Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma. Digestive and Liver Disease, 2013, 45, 612-615.	0.9	10
126	Identification of Combined Genetic Determinants of Liver Stiffness within the SREBP1c-PNPLA3 Pathway. International Journal of Molecular Sciences, 2013, 14, 21153-21166.	4.1	13

#	Article	IF	CITATIONS
127	Genetics and treatment of bile duct stones. Current Opinion in Gastroenterology, 2013, 29, 329-335.	2.3	8
128	PNPLA3-Associated Steatohepatitis: Toward a Gene-Based Classification of Fatty Liver Disease. Seminars in Liver Disease, 2013, 33, 369-379.	3.6	81
129	Gallstone disease in Swedish twins is associated with the Gilbert variant of <i><scp>UGT</scp>1A1</i> . Liver International, 2013, 33, 904-908.	3.9	10
130	Intraperitoneal Catumaxomab Therapy in a Cirrhotic Patient with Malignant Ascites due to Urethelial Carcinoma: A Case Report. Onkologie, 2012, 35, 592-594.	0.8	5
131	The hepatic phosphatidylcholine transporter ABCB4 as modulator of glucose homeostasis. FASEB Journal, 2012, 26, 5081-5091.	0.5	22
132	Common genetic variation in vitamin D metabolism is associated with liver stiffness. Hepatology, 2012, 56, 1883-1891.	7.3	54
133	Genetic study of FGF19 receptor variants in gallstone disease. Hepatology, 2012, 56, 2424-2424.	7.3	3
134	A frequent variant in the human bile salt export pump gene ABCB11 is associated with hepatitis C virus infection, but not liver stiffness in a German population. BMC Gastroenterology, 2012, 12, 63.	2.0	9
135	Prolonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanalicular phospholipid and bile salt transporters. Annals of Hepatology, 2012, 11, 710-714.	1.5	16
136	Phytosterol and cholesterol precursor levels indicate increased cholesterol excretion and biosynthesis in gallstone disease. Hepatology, 2012, 55, 1507-1517.	7.3	43
137	Prolonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanalicular phospholipid and bile salt transporters. Annals of Hepatology, 2012, 11, 710-4.	1.5	5
138	Gallstones: Environment, Lifestyle and Genes. Digestive Diseases, 2011, 29, 191-201.	1.9	78
139	Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: Non-invasive elastography-based study in chronic liver disease. Journal of Hepatology, 2011, 55, 299-306.	3.7	78
140	Dissecting the Genetic Heterogeneity of Gallbladder Stone Formation. Seminars in Liver Disease, 2011, 31, 157-172.	3.6	56
141	Pancreatic cancer risk variantABO rs505922in patients with cholangiocarcinoma. World Journal of Gastroenterology, 2011, 17, 4640.	3.3	5
142	Nonalcoholic fatty liver disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 695-708.	2.4	158
143	Genome-wide association studies and genetic risk assessment of liver diseases. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 669-681.	17.8	68
144	Analysis of the common vasoactive intestinal peptide receptor 1 polymorphism in gallstone patients. Journal of Gastrointestinal and Liver Diseases, 2010, 19, 273-7.	0.9	3

#	Article	IF	CITATIONS
145	Common Variants of <i>ABCB4</i> and <i>ABCB11</i> and Plasma Lipid Levels: A Study in Sib Pairs with Gallstones, and Controls. Lipids, 2009, 44, 521-526.	1.7	31
146	A Variant of the SLC10A2 Gene Encoding the Apical Sodium-Dependent Bile Acid Transporter Is a Risk Factor for Gallstone Disease. PLoS ONE, 2009, 4, e7321.	2.5	36
147	Current Treatments of Primary Sclerosing Cholangitis. Current Medicinal Chemistry, 2007, 14, 2081-2094.	2.4	15
148	The "Hemolysis Model―for the Study of Cyto-Toxicity and Cyto-Protection by Bile Salts and Phospholipids. , 2006, 578, 93-99.		0